THE ADVERSE DRUG REACTIONS OF INTERMITTENT AND DAILY REGIMENS IN THE TREATMENT OF THE INTENSIVE PHASE OF TUBERCULOSIS
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i3.49656Keywords:
Tuberculosis, RNTCP, Intensive phase, Intermittent regimen, Adverse drug reactions, Naranjo algorithm, Modified Hartwig Siegel scale, Daily regimenAbstract
Objective: To study the adverse drug reactions (ADRs) of intermittent and daily anti-tubercular therapy in intensive phase (IP), in patients attending the RNTCP unit, Government Medical College (GMC), Thrissur.
Methods: A prospective observational study was done at the RNTCP unit, GMC, Thrissur, during October 2016-2017. Two hundred and thirty-five patients satisfying inclusion criteria, receiving anti-tubercular therapy as intermittent and daily regimens were selected. Demographic data, risk factors, comorbidities, and investigations were recorded and patients were followed up for IP. Results of investigations, treatment outcome, and ADRs recorded after IP. ADRs were monitored and its causality and severity were assessed. Data were entered in MS Excel and analyzed using SPSS. Qualitative variables are represented as proportions and quantitative as mean and standard deviation. Associations were analyzed using appropriate statistical tests. Analysis was performed using paired t-test p<0.05 taken as significant.
Results: Orange-red urine and secretions were the most common ADR, followed by nausea, fatigue, heartburn, etc. Significant increase in random blood sugar, renal function tests (RFTs), and liver function tests (LFT) after treatment, then before noticed. 84.4% of patients from the daily group and 78% of patients from the intermittent group experienced ADRs. Causality was assessed using Naranjo’s algorithm and severity using a modified Hartwig and Siegel scale.
Conclusion: The majority of patients developed ADRs, which were mild and managed symptomatically. Some reactions required alteration of therapy, reduction of drug dose, or change of suspected drug. To conclude, meticulous monitoring of ADRs in patients on anti-tubercular drugs is mandatory.
Downloads
References
Park K. Park’s Textbook of Preventive and Social Medicine. 18th ed. Jabalpur: M/s Banarsidas Bhanot; 2005. p. 146-61.
Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the antitubercular chemotherapy in the initial intensive phase in non-HIV, sputum positive, pulmonary tuberculosis patients. J Clin Diagn Res 2013;7:292.
Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampicin and pyrazinamide in patients hospitalised for pulmonary tuberculosis. Eur Respir J 1996;9:2026-30.
Dedun AR, Borisagar GB, Solanki RN. Impact of adverse drug reaction of first line anti-tuberculous drugs on treatment outcome of tuberculosis under revised national tuberculosis control programme. Int J Adv Med 2017;4:645-9.
Sinha K, Marak IT, Singh WA. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy: Experience at an outpatient clinic of a teaching hospital in the city of Imphal, Manipur, India. J Assoc Chest Phys 2013;1:50.
Chhetri AK, Saha A, Verma SC, Palaian S, Mishra P, Sankar PR. A study of adverse drug reactions posed by first line anti-tubercular drugs used in Directly Observed Treatment, Short course (DOTS) therapy in Western Nepal, Pokhara. J Pak Med Assoc 2008;58:531-6.
Hochberg NS, Sarkar S, Horsburgh CR Jr., Knudsen S, Pleskunas J, Sahu S, et al. Comorbidities in pulmonary tuberculosis cases in Puducherry and Tamil Nadu, India: Opportunities for intervention. PLoS One 2017;12:e0183195.
Prakasha SR, Suresh G, Souza IP, Kumar SG, Rao R, Shetty M. A study of clinical characteristics and trend of different types of tuberculosis in coastal South India. Ann Trop Med Public Health 2012;5:489.
Sharma A, Kansal D, Katoch K, Sharma PK, Bansal R, Sharma T. Pattern of adverse drug reactions in new smear positive patients of pulmonary tuberculosis treated under directly observed treatment short course. Int J Basic Clin Pharmacol 2017;5:1397-401.
Published
How to Cite
Issue
Section
Copyright (c) 2023 Dr Anu Eline Mathew, Dr Vishnu R, Dr Minu Baby, Dr Anand R G
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.